Application of dual affinity retargeting molecules to
achieve optimal redirected T-cell killing of B-cell lymphoma
by Paul A. Moore, Wenjun Zhang, G. Jonah Rainey, Steve Burke, Hua Li, Ling
Huang, Sergey Gorlatov, Maria Concetta Veri, Sudeepta Aggarwal, Yinhua Yang,
Kalpana Shah, Linda Jin, Sunan Zhang, Leilei He, Tengfei Zhang, Valentina
Ciccarone, Scott Koenig, Ezio Bonvini, and Syd Johnson
Blood
Volume 117(17):4542-4551
April 28, 2011
©2011 by American Society of Hematology
CD19xCD3 DART and BiTE molecules are highly purified and capable of simultaneous
engagement of both targets.
Paul A. Moore et al. Blood 2011;117:4542-4551
©2011 by American Society of Hematology
CD19xCD3 DART molecule mediates enhanced redirected killing of B-cell lymphoma.
Paul A. Moore et al. Blood 2011;117:4542-4551
©2011 by American Society of Hematology
CD19xTCR DART molecule is highly purified and binds both of its target cells.
Paul A. Moore et al. Blood 2011;117:4542-4551
©2011 by American Society of Hematology
Enhanced redirected immune cell killing and T-cell activation by the DART molecule.
Paul A. Moore et al. Blood 2011;117:4542-4551
©2011 by American Society of Hematology
Autologous B-cell depletion by the DART molecule and dependence on coengagement for T-cell
proliferation.
Paul A. Moore et al. Blood 2011;117:4542-4551
©2011 by American Society of Hematology
DART molecules mediate the cell-cell association.
Paul A. Moore et al. Blood 2011;117:4542-4551
©2011 by American Society of Hematology
CD19xTCR DART molecule inhibits B-cell lymphoma.
Paul A. Moore et al. Blood 2011;117:4542-4551
©2011 by American Society of Hematology